<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72106">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02167035</url>
  </required_header>
  <id_info>
    <org_study_id>TEP001</org_study_id>
    <nct_id>NCT02167035</nct_id>
  </id_info>
  <brief_title>Comparison of Combigan BID Versus Simbrinza TID</brief_title>
  <official_title>Pilot Study Comparison of Combigan BID vs Simbrinza TID in Subjects Currently Treated With Latanoprost For Open-Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cornerstone Health Care, PA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cornerstone Health Care, PA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare Combigan BID vs Simbrinza TID in subjects currently being treated with
      Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both of these drugs are
      currently FDA approved as combination therapy for patients with Open-Angle Glaucoma or
      Ocular Hypertension. The purpose of this clinical trial would be to assess which treatment,
      if either, is superior in lowering intraocular pressure (IOP). A secondary objective is to
      assess the tolerability of each drug.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra Ocular Pressure</measure>
    <time_frame>Day 90</time_frame>
    <description>The Intra Ocular Pressure will be assessed on study subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>Day 90</time_frame>
    <description>A questionnaire will be used to determine how subject tolerated study drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Combigan BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combigan 0.2%/0.5% one drop BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simbrinza TID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Simbrinza 1/0.2% one drop TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combigan BID</intervention_name>
    <arm_group_label>Combigan BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simbrinza TID</intervention_name>
    <arm_group_label>Simbrinza TID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Open-angle glaucoma or ocular Hypertension

          -  Currently treated with Latanoprost for min of 6 weeks

          -  Male or Female 18 yrs and older

          -  Best Corrected Visual Acuity 20/100 or better in both eyes

          -  Pachymetry &gt;470 and &lt; 640

          -  Women of childbearing potential must have a negative urine pregnancy test at the
             screening/baseline visit

          -  Patient willing and capable of providing informed consent

        Exclusion Criteria:

          -  C/D &gt; 0.8

          -  Visual field loss, which in the opinion of the investigator is functionally
             significant

          -  Current use of ocular steroids

          -  Concurrent significant active ocular disease History (within 3 months prior to
             Screening) of ocular laser, intraocular, filtering or refractive surgery or planned
             ocular surgery of any kind during study participation

          -  Change within prior 30 days or anticipated change in any systemic medication that is
             known to affect IOP

          -  Uncontrolled systemic disease

          -  Significant ocular hyperemia at baseline

          -  Prior glaucoma procedure within 3 months

          -  Females who are pregnant, nursing, or planning a pregnancy or who are of childbearing
             potential and not using a reliable method of contraception

          -  Known allergy or sensitivity to any study medication

          -  Asthma or any other known medical condition that the investigator feels would put
             patient at increased risk from any of the study medications

          -  Current enrollment in an investigational drug or device study or participation in
             such a study within 30 days prior to Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael E Tepedino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cornerstone Health Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chelsea R Allred</last_name>
    <phone>336-802-2255</phone>
    <email>chelsea.allred@cornerstonehealthcare.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cornerstone Health Care</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea R Allred</last_name>
      <phone>336-802-2255</phone>
      <email>chelsea.allred@cornerstonehealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Michael E Tepedino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 20, 2017</lastchanged_date>
  <firstreceived_date>June 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cornerstone Health Care, PA</investigator_affiliation>
    <investigator_full_name>Michael Tepedino MD</investigator_full_name>
    <investigator_title>Director of Clinical Research</investigator_title>
  </responsible_party>
  <keyword>Open-Angle Glaucoma</keyword>
  <keyword>Ocular Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brimonidine Tartrate, Timolol Maleate Drug Combination</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
